Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STERITALC vs ETHAMOLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sterile talc (STERITALC) induces pleural inflammation and fibrosis, leading to adhesion of the pleural layers. This mechanism is mediated by activation of mesothelial cells and fibroblasts, resulting in release of inflammatory cytokines and growth factors.
Ethamolin (ethanolamine oleate) is a sclerosing agent that causes irritation of the vascular endothelium, leading to thrombosis, inflammation, and fibrosis of the vein wall, resulting in obliteration of varicose veins or esophageal varices.
Pleurodesis for malignant pleural effusion,Pleurodesis for recurrent pneumothorax,Pleurodesis for chylothorax (off-label)
FDA-approved: Treatment of esophageal varices that have recently bled to prevent rebleeding.,Off-label: Sclerotherapy of varicose veins, treatment of hemorrhoids, management of vascular malformations.
Sterile talc powder for intrapleural administration: 4-8 g mixed with 50-250 m L normal saline, instilled via chest tube for pleurodesis. Single dose typically used.
5% solution intravenously, 0.1-0.3 m L per injection site, maximum 5 m L per site, repeated at 5-7 day intervals if needed.
Not applicable; talc particles are not metabolized and remain in the pleural space indefinitely, with gradual clearance over months to years via macrophage uptake and lymphatic drainage.
Terminal elimination half-life is approximately 5-6 hours in adults with normal renal function; may be prolonged in renal impairment.
Talc is an inert mineral; not metabolized. Systemic absorption may lead to deposition in tissues, but no specific metabolic pathway exists.
Ethanolamine oleate is metabolized in the liver via oxidation and conjugation; exact enzymes are not well characterized.
Sterile talc (STERITALC) is not absorbed systemically following intrapleural administration. Excretion occurs locally via phagocytosis and clearance by pleural lymphatics; no significant renal, biliary, or fecal elimination applies.
Primarily renal excretion of unchanged drug and metabolites; >90% eliminated in urine within 24 hours, with less than 5% in feces.
Not applicable; talc is an inorganic silicate, does not bind to plasma proteins.
Approximately 20-30% bound to plasma proteins, primarily albumin.
Not applicable; talc remains at the site of administration (pleural space) with negligible systemic distribution.
Volume of distribution is approximately 0.5-0.8 L/kg, indicating distribution into extracellular fluid.
Not applicable; administered via intrapleural instillation and acts locally. No systemic absorption is intended or occurs.
Intravenous: 100%; intramuscular: approximately 90-95% due to first-pass metabolism.
No dose adjustment required for renal impairment.
No dose adjustment required for renal impairment.
No dose adjustment required for hepatic impairment.
Contraindicated in severe hepatic disease (Child-Pugh class C). Use with caution in Child-Pugh class A or B; no specific dose modification established.
Safety and efficacy not established in pediatric patients; use not recommended.
Not recommended for use in children due to lack of safety and efficacy data.
No specific dose adjustment; consider general precautions for elderly due to potential comorbidities.
Use with caution; consider reduced dose due to increased risk of sclerotherapy complications. No specific dose adjustments established.
Risk of acute respiratory distress syndrome (ARDS), pneumonitis, and granulomatous inflammation secondary to talc particle absorption. Use only as a sterile, asbestos-free talc slurry or poudrage. Avoid systemic absorption.
None explicitly required by FDA; however, severe adverse effects including anaphylaxis, renal failure, and esophageal ulceration have been reported.
Use only sterile, asbestos-free talc,Monitor for respiratory distress, pneumothorax, or re-expansion pulmonary edema,Avoid in patients with empyema or active pleural infection,Caution in patients with compromised pulmonary function,Risk of fever, chest pain, and pleural effusion recurrence
Risk of anaphylaxis and hypersensitivity reactions; have emergency equipment available.,Risk of esophageal ulceration, stricture, or perforation when used for varices.,May cause hemolysis and hemoglobinuria; monitor renal function.,Use caution in patients with cardiopulmonary disease, as rapid injection may cause bradycardia or hypotension.
Hypersensitivity to talc,Pleural infection or empyema,Severe respiratory insufficiency,Pregnancy and lactation (relative contraindication),Uncontrolled bronchopleural fistula
Known hypersensitivity to ethanolamine oleate or any component.,Active gastrointestinal bleeding (for elective sclerotherapy).,Severe hepatic impairment or portal hypertension with high risk of perforation.,Uncontrolled systemic infection.
No known food interactions. Maintain normal diet unless otherwise instructed by physician.
No specific food interactions. Avoid oral intake immediately after procedure until gag reflex returns.
Insufficient human data; animal studies not conducted. Sterile talc is not absorbed systemically when used for pleurodesis, thus minimal fetal exposure. However, talc may cause maternal inflammation and fever, which could theoretically increase risk of preterm labor or fetal distress in third trimester. Use in pregnancy only if clearly needed.
Pregnancy Category D. Positive evidence of human fetal risk: Ethamolin (ethanolamine oleate) is contraindicated in pregnant women due to known teratogenicity in animal studies and potential for fetal harm. No adequate, well-controlled studies in pregnant women.
No data on excretion into breast milk. Due to lack of systemic absorption after pleural administration, transfer into milk is unlikely. Caution advised; consider risk-benefit.
It is not known whether ethanolamine oleate is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio: Not available.
No dose adjustment necessary due to minimal systemic absorption. Use standard pleurodesis dose (typically 2-5 g as slurry or poudrage).
No specific dosing adjustments are recommended for pregnancy; however, use is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, altered protein binding) may affect drug distribution, but no dose adjustment studies exist. Avoid use unless benefit clearly outweighs risk.
STERITALC (talc) is used for pleurodesis in malignant pleural effusion or recurrent pneumothorax. Administer via chest tube as a slurry or poudrage. Monitor for chest pain, fever, and hypoxia post-instillation. Ensure lung re-expansion before use to avoid trapped lung. Do not use in patients with empyema or bronchopleural fistula.
Ethamolin (ethanolamine oleate) is a sclerosing agent used for esophageal varices. Administer via intravariceal injection; maximum dose per session is 20 m L. Monitor for anaphylaxis, chest pain, and esophageal ulceration. Do not use in patients with known hypersensitivity to ethanolamine or oleic acid.
You may experience chest pain, fever, or shortness of breath after the procedure.,The medication causes the layers of your lung to stick together to prevent fluid or air buildup.,Report any severe pain, difficulty breathing, or signs of infection immediately.,Avoid strenuous activity and keep the chest tube site clean and dry.,Follow up with your doctor for imaging to confirm pleurodesis effectiveness.
This medication is injected into the veins in your esophagus to stop bleeding.,You may experience chest pain or difficulty swallowing after the procedure.,Avoid eating or drinking until the numbing medicine wears off to prevent choking.,Report any signs of allergic reaction, such as hives, difficulty breathing, or swelling.,Follow up with your doctor for repeat procedures as needed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STERITALC vs ETHAMOLIN, answered by our medical review team.
STERITALC is a Sclerosing Agent that works by Sterile talc (STERITALC) induces pleural inflammation and fibrosis, leading to adhesion of the pleural layers. This mechanism is mediated by activation of mesothelial cells and fibroblasts, resulting in release of inflammatory cytokines and growth factors.. ETHAMOLIN is a Sclerosing Agent that works by Ethamolin (ethanolamine oleate) is a sclerosing agent that causes irritation of the vascular endothelium, leading to thrombosis, inflammation, and fibrosis of the vein wall, resulting in obliteration of varicose veins or esophageal varices.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STERITALC and ETHAMOLIN depend on the specific clinical indication. These are both Sclerosing Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STERITALC is: Sterile talc powder for intrapleural administration: 4-8 g mixed with 50-250 m L normal saline, instilled via chest tube for pleurodesis. Single dose typically used.. The standard adult dose of ETHAMOLIN is: 5% solution intravenously, 0.1-0.3 m L per injection site, maximum 5 m L per site, repeated at 5-7 day intervals if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STERITALC and ETHAMOLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STERITALC is classified as Category C. Insufficient human data; animal studies not conducted. Sterile talc is not absorbed systemically when used for pleurodesis, thus minimal fetal exposure. However, talc may cause mat. ETHAMOLIN is classified as Category C. Pregnancy Category D. Positive evidence of human fetal risk: Ethamolin (ethanolamine oleate) is contraindicated in pregnant women due to known teratogenicity in animal studies and . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.